查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
DNA 編碼庫：平台與服務市場（第二版），2023-2035
市場調查報告書
商品編碼
1358248

DNA 編碼庫：平台與服務市場（第二版），2023-2035

DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 278 Pages | 商品交期: 最快1-2個工作天內

價格

DNA 編碼文庫（也稱為 DEL）因其相對於高通量篩選的優勢而成為一種優雅的組合藥物發現工具，用於合成和篩選大量小分子化合物。 有趣的是，包含多達 40 兆個不同分子的 DNA 編碼庫已被開發出來，可用於篩選、鑑定命中化合物以及發現藥理學先導化合物，如大環化合物、天然產物和小分子。 此外，單一 DNA 編碼庫已被證明是針對獨特的不可治療標靶優化先導化合物的有用工具，從而加速藥物開發過程。

此外，隨著使用 DEL 技術自動篩選小分子有機配體，現在可以在短短幾天的時間內識別出潛在的先導分子。 因此，許多製藥公司和學術研究機構都在投資這項技術，以加速藥物發現過程，更快地為患者帶來新的治療方法。 此外，DNA 編碼文庫已被發現具有藥物發現以外的其他用途。 例如，2022 年，X-Chem 與 Enko 建立了合作，以增強 Enkompass 平台，以開發專注於作物保護的解決方案。

DNA 編碼化學庫平台可存取市場上最大的化學空間，非常適合人工智慧和機器學習提供的大數據分析和建模技術。 因此，一些公司正在透過將人工智慧和機器學習整合到 DNA 編碼庫中來抓住這一機會，其中包括 Insitro，一家領先的藥物發現機器學習公司，於 2020 年收購了 Haystack Sciences。 Insitro 進行此次收購是為了利用 Haystack Sciences 的 DNA 定序技術並增強其基於機器學習的藥物發現能力。 此外，Google研究院還在 2020 年與 X-Chem 合作，開發了一種利用物理和虛擬篩選尋找生物活性分子的有效方法。

在 DNA 編碼文庫市場中，多個利益相關者正在與其他行業/非行業參與者結盟，以進行平台和產品許可、研究和開發以及產品開發。 自 2010 年以來，DNA 編碼文庫市場已建立超過 175 個策略合作夥伴關係。 2023 年簽署的合作關係的一個顯著例子是 Orbit Discovery 和 SanegeneBio 之間的一項研究協議，旨在識別和優化針對致病基因的命中。

DNA 編碼庫在藥物發現方面的多項優勢使利害關係人能夠專注於 DNA 編碼庫的各個方面，以擴展其能力並建立全面的產品/服務組合，並收購其他行業參與者。 2021年10月，X-Chem收購了生物技術公司Glamorous.AI，將人工智慧納入其DNA編碼文庫，並在DNA編碼文庫市場上作為一站式商店運作。

到 2023 年，全球 DNA 編碼文庫市場預計價值 8.4 億美元。 目前，市場似乎由兩種商業模式所驅動。 第一個是將其專有的 DNA 編碼圖書館平台授權給有興趣的客戶，第二個是收取使用自己的圖書館進行研究的服務費。 一旦利用 DNA 編碼庫進行藥物發現的承諾得以實現，商業模式將變得更加協作。 大型製藥公司的存在可能在建立產業對 DEL 技術的信心方面發揮重要作用

本報告考察了全球 DNA 編碼文庫市場，並提供了市場概況，包括藥物開發和市場格局概述、區域趨勢以及進入市場的公司概況。

目錄

第 1 章前言

第 2 章執行摘要

第 3 章簡介

第 4 章市場狀況

第 5 章商業模式分析

第 6 章企業競爭力分析

第 7 章公司簡介

  • 章節概述
  • AlphaMa
  • DICE Therapeutics
  • DyNAbind
  • HitGen
  • NovAliX
  • Vipergen
  • WuXi AppTec
  • X-Chem

第 8 章夥伴關係與協作

第 9 章融資與投資分析

第 10 章專利分析

第 11 章主要藥廠的舉措

第 12 章案例研究：支持 DNA 編碼庫開發的公司/組織

第 13 章市場預測與機會分析

第 14 章結論

第 15 章管理見解

第 16 章附錄 1：表格資料

第 17 章附錄 2：公司與組織名單

Product Code: RA100415

INTRODUCTION

The global DNA encoded library market is estimated to be worth USD 840 million in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 16.04% during the forecast period 2023-2035.

Over the years, DNA encoded libraries have emerged as a powerful platform for drug discovery, enabling the synthesis and screening of millions of small molecules in a single study. DNA encoded libraries are collections of small molecules attached with DNA tags, which serve as barcodes to identify the molecules. Further, the use of DNA encoded chemical library has gained momentum in recent years due to their ability to accelerate the drug discovery process by reducing the time and cost associated with traditional high-throughput screening methods. Moreover, the increasing demand for innovative therapies to treat complex diseases, such as oncological disorders and neurological disorders, has led to a surge in the development of DNA encoded libraries. Additionally, the growing adoption of DNA encoded chemical library by pharmaceutical and biotechnology companies, academic institutions and contract research organizations has further propelled the market growth of this industry. Driven by the ongoing pace of innovation in this field and sufficient financial support from investors, the DNA encoded library market is likely to witness substantial growth during the forecast period.

SCOPE OF THE REPORT

"The DNA Encoded Library Market: Platforms and Services (2nd Edition), 2023-2035 - Distribution by Application Area (Hit Generation / Identification, Hit to Lead, Hit Validation / Optimization and Other Application Areas), Therapeutic Area (Oncological Disorders, Immunological Disorders, Neurological Disorders, Respiratory Disorders, Dermatological Disorders, Cardiovascular Disorders, Infectious Diseases and Other Therapeutic Areas), End-users (Pharma / Biopharma Industry, Academic / Research Institute and Other End-users), Type of Payment Model Employed (Upfront Payment and Milestone Payment) and Key Geographical Regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China): Industry Trends and Global Forecasts market report" features an extensive study of the current market landscape, market size and future opportunities for the DNA encoded library companies, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the DNA encoded library market report are briefly discussed below.

Growing Interest in DNA Encoded Library for Lead Screening and Lead Optimization

DNA encoded libraries (also known as DELs), owing to their advantages over high-throughput screening, have emerged to be a sophisticated combinatorial drug discovery tool for the synthesis and screening of large collections of small molecule compounds. Interestingly, DNA encoded libraries encompassing as high as 40 trillion different molecules has been developed, enabling screening, hit identification and discovery of pharmacological leads, such as macrocycles, natural products and small molecules. Furthermore, single DNA encoded library has proven to be a helpful tool in lead optimization against undruggable and unique targets and accelerating the drug development process.

Moreover, the introduction of automated screening of small organic ligands using DEL technology has enabled the identification of potential lead molecules within a time span of a few days. As a result, a large number of pharmaceutical companies and academic / research institutions are investing in this technology to accelerate the drug discovery process and bring new treatments to patients faster. Furthermore, it has been observed that DNA encoded library is being applied for purposes beyond drug discovery. For instance, a collaboration was established in 2022 between X-Chem and Enko to enhance the Enkompass platform for the development of solutions focused on crop protection.

Competitive Landscape Analysis: DNA Encoded Library Companies

DNA encoded library market landscape features the presence of close to 50 large, mid-sized and small companies offering various services related to DNA encoded libraries for the purpose of drug discovery, including hit identification, hit optimization / validation and lead generation. It is worth highlighting that several big pharma companies are also using DNA encoded libraries for drug discovery. For instance, Amgen uses its DNA encoded library (owned post-acquisition of Nuevolution) for in-house drug development purposes. Other big pharma companies such as GSK, Pfizer, Roche, Novartis, AstraZeneca, Bristol Myers Squibb, Sanofi and Janssen are also using DEL technology either through in-house capability or collaboration with a DEL technology / service provider.

Technology Analysis: Emergence of Artificial Intelligence and Machine Learning in DNA Encoded Library Market

Owing to its access to the largest chemical space available in the market, DNA encoded chemical library platforms are a natural fit for big data analytics and modeling technologies offered by artificial intelligence and machine learning. As a result, some companies have been pursuing this opportunity by integrating artificial intelligence and machine learning in DNA encoded libraries, including Insitro, a leading player in machine learning for drug discovery, which acquired Haystack Sciences in 2020. Insitro made the acquisition to leverage Haystack Sciences DNA sequencing technology to enhance its machine learning based drug discovery capability. Additionally, Google Research also collaborated with X-Chem in 2020 to develop an effective method for finding biologically active molecules using physical and virtual screening. Further, in 2021, Relay Therapeutics acquired ZebiAI for USD 85 million upfront, allowing them to incorporate the machine learning based DNA encoded chemical library technology into their protein targeting platform, Dynamo.

Strategic Alliances and Acquisitions have Fueled DNA Encoded Library Market Growth

Several stakeholders have been forging alliances with other industry / non-industry players in DNA encoded library market for platform and product licensing, research and development and product development purposes. It is worth highlighting that, since 2010, over 175 strategic partnerships have been inked in the DNA encoded library market. A notable example of partnership inked in 2023 includes research agreement between Orbit Discovery and SanegeneBio to identify and optimize hits focused on the disease-causing gene.

Owing to several advantages of DNA encoded libraries in drug discovery, the stakeholders are also acquiring other industry players specializing in various aspects of DNA encoded library in order to expand their capabilities and to build a comprehensive product / service portfolio. In October 2021, X-Chem acquired Glamorous.AI, a biotechnology firm, to incorporate artificial intelligence in DNA encoded libraries and operate as a one-stop-shop in the DNA encoded library market.

Market Trends Analysis: Increase in Funding and Intellectual Property Landscape Reflect the Rising Interest in DNA Encoded Chemical Library Market

The growing interest in DNA encoded library market can be validated by the fact that in the last two years, close to USD 2.5 billion has been invested by several investors based across the globe, in companies engaged in the development of DNA encoded libraries. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Relay Therapeutics and DiCE Therapeutics are the leading DNA encoded library companies, owing to the secondary offerings received in 2022, respectively.

Interestingly, the patent filing activity in the industry has also witnessed a growth rate of over 20%, in the last decade. Consistent support from the venture capital firms is anticipated to ensure the development of more advanced DNA encoded chemical libraries.

Market Analysis: DNA Encoded Library Market Size

The global DNA encoded library market is estimated to be worth USD 840 million in 2023. Currently, the market is likely to be driven by two business models; the first involves the out-licensing of proprietary DNA encoded library platforms to interested clients and the second involves charging fee-for-service to conduct research using their libraries. As the promise of DNA encoded library-based drug discovery is realized, the business models will become more collaborative in nature. The presence of big pharmaceuticals will play a major role in establishing the confidence of the industry in DEL technology. In late 2021, Amgen moved one of its small molecule drugs AMG 193, identified using Amgen's proprietary DEL technology, to phase I/II clinical trial. The trial is active and recruiting participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The market size is expected to grow at a CAGR of 16.04% during the forecast period, mainly driven by the number of DNA encoded library discovered small molecule drugs reaching clinical trials.

Regional Analysis: North America to Hold the Largest DNA Encoded Library Market Share

In the past few years, several well-funded start-ups / small companies, offering DNA encoded library platforms and associated services have been established. Of these, the majority of companies are headquartered in North America and Europe. Consequently, more than 70% of the global market of DNA encoded libraries is anticipated to be captured by players based in North America and Europe, in 2035. These companies will support the drug discovery initiatives of pharmaceutical drug developers, generating revenues through out-licensing or fee-for-service models.

Leading DNA Encoded Library Companies

Examples of the key DNA encoded library companies (the complete list of players is available in the full report) include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec and X-Chem. This market report also includes an easily searchable excel database of all the DNA encoded library companies worldwide.

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA encoded library market and its evolution in the mid to long term.
  • A general overview of DNA encoded libraries, along with the information on the encoding strategies for library construction, comparison of traditional libraries and DNA encoded libraries, key advantages and challenges within this market.
  • A detailed assessment of the overall landscape of DNA encoded library service providers / platform providers / in-house companies, based on various relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, type of organization (academic / research institute, biopharmaceutical, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) and contract research organization (CRO)), library size (<1 billion, 1-10 billion and >10 billion), library synthesis method(s) (DNA-conjugate, self-assembled, DNA-directed and unspecified library synthesis method), library screening method(s) (conventional screening, Artificial Intelligence (AI) / Machine Learning (ML)-based screening and unspecified screening method), type of product(s) offered (proprietary library, DEL synthesis package / kit and ancillary tools), type of service(s) offered (type of library design service(s) offered - codon (oligo) sequence design and synthesis and custom library design / synthesis, and type of library screening service(s) offered - hit identification, hit optimization / validation, hit to lead, sequencing, data analysis and other / unspecified services offered), type of pharmacological lead(s) (small molecules, macrocycles / peptides and other / unspecified molecules), therapeutic target(s) (G protein-coupled receptors, protein-protein interactions, enzyme targets, membrane proteins, nucleic acids, undruggable biological targets and other / unspecified therapeutic target), therapeutic area(s) (oncological disorders, cardiovascular disorders, neurodegenerative disorders, inflammatory disorders, metabolic disorders, infectious diseases, ophthalmic disorders and other / unspecified therapeutic areas) and end-user(s) (academic / research institute and pharma / biopharma industry).
  • A detailed analysis of various business models adopted by the companies providing DNA encoded library platforms and services, include operational model, service centric model and product centric model.
  • A detailed competitiveness analysis of DNA encoded libraries platform and service providers based on supplier strength (in terms of year of establishment and company size) and company competitiveness (in terms of type of business model, number of products offered, number of services offered, number of platforms, number of pharmacological leads, number of therapeutic area and number of therapeutic target).
  • Elaborate profiles of the prominent platform and service providers (shortlisted based on a proprietary criterion) engaged in this market. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), DNA encoded library platform and service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of the partnerships inked between industry / non-industry stakeholders engaged in this industry, since 2010, covering research agreements, R&D agreements, license agreements (specific to technology platforms and product candidates), product development agreements, product development and commercialization agreements, mergers and acquisitions and other relevant agreements.
  • An analysis of funding and investments that have been made into companies having proprietary DNA encoded chemical library, including venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place during the period 2018 to 2023, highlighting the growing interest of venture capital (VC) community and other strategic investors in this market.
  • An in-depth analysis of various patents that have been filed / granted related to DNA encoded chemical library, since 2005, taking into consideration several parameters, such as publication year, application year, patent jurisdiction, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, the chapter includes a detailed patent benchmarking and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
  • A detailed analysis of various DNA encoded libraries focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2022), featuring heat map representations that highlight the distribution of top pharmaceutical companies and spider web representations, comparing the initiatives of big pharma players based on multiple relevant parameters.
  • A case study on companies / organizations that are presently engaged in supporting the development of DNA encoded libraries. Further, chapter also includes analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of organization (pharma / biopharma industry and academic / research institutes) and types of support services / ancillary tools offered (building blocks, oligos, scaffolds and other support services / ancillary tools).

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the DNA encoded library market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035, Additionally, historical trend of the market has also been presented for the time period, 2017-2022. Further, our year-wise projections of the current and forecasted opportunity have been segmented based on relevant parameters, such as application areas (hit generation / identification, hit to lead, hit validation / optimization and other application areas), therapeutic area (oncological disorders, immunological disorders, neurological disorders, respiratory disorders, dermatological disorders, cardiovascular disorders, infectious diseases and other therapeutic areas), end-user (pharma / biopharma industry, academic / research institute and other end-users), type of payment method (upfront payment and milestone payment) and key geographical regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.

The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report also features detailed transcripts of interviews held with various industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What is a DNA encoded library?

Answer: A DNA encoded library is a collection of small molecules attached with DNA-tags that have unique information about the identity and the structure of each library member. DNA encoded library platform enables efficient synthesis, handling and interrogation of vast number of chemically synthesized drug-like compounds.

Question 2: What is DNA encoded library screening?

Answer: The high-throughput screening capability of DNA encoded libraries allows for the rapid identification of potential drug candidates, making them particularly useful in the early stages of drug discovery when a large number of compounds need to be tested.

Question 3: How are DNA encoded libraries made?

Answer: The development of a DNA encoded library is based on tagging small molecules / organic leads with short DNA sequences and then utilizing combinatorial chemistry to generate a huge number of structurally and functionally varied compounds with unique DNA tags.

Question 4: How is information in DNA encoded?

Answer: Presently, DNA-recorded synthesis formats are widely used to encode information in DNA, which involve a series of reactions in the solution phase. Apart from this, encoding by ligation of single-stranded oligonucleotide, encoding by ligation of double-stranded oligonucleotide and encoding by polymerase-catalysed fill-in reaction are some of the encoding strategies used for encoding the information in DNA.

Question 5: How DNA encoded libraries are revolutionizing drug discovery?

Answer: DNA encoded libraries have transformed drug discovery by providing a diverse range of compounds that can be screened for potential drugs. This method is faster and more efficient than traditional screening methods and can identify novel compounds that may have been missed otherwise. It also provides valuable information on the structure and interactions of lead molecules.

Question 6: What are the advantages of DNA encoded library?

Answer: DNA encoded library technology is very helpful during the early stages of drug discovery since it requires less investment, time and storage space to identify target compounds. Apart from these, there are several other advantages as well, such as cost-effective process, rapid screening of large number of leads and hit identification against undruggable targets.

Question 7: How many companies are developing DNA encoded libraries?

Answer: Presently, close to 50 companies are offering services related to DNA encoded libraries for the purpose of drug discovery. Majority of the encoded libraries are designed to identify leads against protein pump inhibitors, which are otherwise difficult to screen using traditional libraries.

Question 8: Which type of business model is widely adopted by companies in DNA encoded library market?

Answer: The DNA encoded library market is likely to be driven by two business models; the first involves out-licensing of proprietary library platforms to interested clients and the second involves charging fee-for-service to conduct research using their libraries.

Question 9: What is the current landscape of patents filed for DNA encoded libraries?

Answer: A total of 403 patents have been filed in the field of DNA encoded libraries. Of these, 277 patents are patent applications, while 114 are granted patents. Of the total granted patents, around 65% patents have been filed in the US.

Question 10: Who are the key players in the DNA encoded library market?

Answer: Examples of key players engaged in DNA encoded library market (which have also been captured in this report) include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec and X-Chem.

Question 11: What are the leading market segments in the global DNA encoded library market?

Answer: In terms of type of therapeutic area, oncological disorders currently account for the largest share (35%) of the global DNA encoded library market. Further, in terms of application area, hit generation / identification is likely to capture over 60% of the current and future market.

Question 12: Which region captures the largest share in the DNA encoded library market?

Answer: Presently, the DNA encoded library market is dominated by North America, capturing around 45% of the overall market size.

Question 13: What is the likely growth rate (CAGR) for DNA encoded library market?

Answer: The DNA encoded library market is projected to grow at an annualized rate (CAGR) of ~17%, during the forecast period 2023-2035.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an overview to the full report, DNA Encoded Library Market: Platforms and Services (2nd Edition), 2023-2035.
  • Chapter 2 is an executive summary of the insights captured during our research. It presents a high-level view on the current scenario within the DNA encoded library market and its evolution in the mid to long term.
  • Chapter 3 provides a general overview of DNA encoded libraries, along with the information on the encoding strategies for library construction, comparison of traditional libraries and DNA encoded libraries, key advantages and challenges associated in this domain.
  • Chapter 4 includes detailed assessment of the overall landscape of DNA encoded library service providers / platform providers / in-house companies, based on various relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, type of organization (academic / research institute, biopharmaceutical, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) and contract research organization (CRO)), library size (<1 billion, 1-10 billion and >10 billion), library synthesis method(s) (DNA-conjugate, self-assembled, DNA-directed and unspecified library synthesis method), library screening method(s) (conventional screening, Artificial Intelligence (AI) / Machine Learning (ML)-based screening and unspecified screening method), type of product(s) offered (proprietary library, DEL synthesis package / kit and ancillary tools), type of service(s) offered (type of library design service(s) offered - codon (oligo) sequence design and synthesis and custom library design / synthesis, and type of library screening service(s) offered - hit identification, hit optimization / validation, hit to lead, sequencing, data analysis and other / unspecified services offered), type of pharmacological lead(s) (small molecules, macrocycles / peptides and other / unspecified molecules), therapeutic target(s) (G protein-coupled receptors, protein-protein interactions, enzyme targets, membrane proteins, nucleic acids, undruggable biological targets and other / unspecified therapeutic target), therapeutic area(s) (oncological disorders, cardiovascular disorders, neurodegenerative disorders, inflammatory disorders, metabolic disorders, infectious diseases, ophthalmic disorders and other / unspecified therapeutic areas) and end-user(s) (academic / research institute and pharma / biopharma industry).
  • Chapter 5 provides a detailed analysis of various business models adopted by the companies providing DNA encoded libraries platforms and services, including operational model, service centric model and product centric model.
  • Chapter 6 provides a detailed competitiveness analysis of DNA encoded libraries platform and service providers based on supplier strength (in terms of years of establishment and company size) and company competitiveness (in terms of type of business model, number of products offered, number of services offered, number of platforms, number of pharmacological leads, number of therapeutic area and number of therapeutic target).
  • Chapter 7 provides detailed profiles of the prominent platform and service providers (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), DNA encoded library platform and service portfolio, recent developments and an informed future outlook.
  • Chapter 8 includes detailed analysis of the partnerships inked between stakeholders engaged in this domain, since 2010, covering research agreements, R&D agreements, license agreements (specific to technology platforms and product candidates), product development agreements, product development and commercialization agreements, mergers and acquisitions and other relevant agreements.
  • Chapter 9 provides details on the various funding and investments that have been made into companies having proprietary DNA encoded libraries, including venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place in the period between 2018 to 2023, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
  • Chapter 10 features an in-depth analysis of various patents that have been filed / granted related to DNA encoded libraries, since 2005, taking into consideration parameters, such as publication year, patent jurisdiction, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • Chapter 11 features a detailed analysis of various DNA encoded libraries focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2022), featuring a heat map representation that highlights the distribution of top pharmaceutical companies and a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
  • Chapter 12 features a case study on companies / organizations that are presently engaged in supporting the development of DNA encoded libraries. Further, chapter also includes analysis based on various relevant parameters such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of organization (pharma / biopharma industry and academic / research institutes) and types of support services / ancillary tools offered (building blocks, oligos, scaffolds and other support services / ancillary tools).
  • Chapter 13 presents a comprehensive market forecast and opportunity analysis, highlighting the future potential of the DNA encoded library market, till 2035. We have segregated the current and upcoming opportunity based on relevant parameters, such as application areas (hit generation / identification, hit to lead, hit validation / optimization and other application areas), therapeutic area (oncological disorders, immunological disorders, neurological disorders, respiratory disorders, dermatological disorders, cardiovascular disorders, infectious diseases and other therapeutic areas), end-users (pharma / biopharma industry, academic / research institute and other end-users), type of payment model employed (upfront payment and milestone payment) and key geographical regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China).
  • Chapter 14 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 15 provides the transcripts of interviews conducted with key stakeholders in this industry.
  • Chapter 16 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. DNA Encoded Library Market Overview
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Drug Development
  • 3.3. Drug Discovery Process
    • 3.3.1. Target Identification
    • 3.3.2. Target Validation
    • 3.3.3. Hit Generation
      • 3.3.3.1. High-throughput Screening
      • 3.3.3.2. Fragment-based Screening
      • 3.3.3.3. Virtual Screening
      • 3.3.3.4. DNA Encoded Library Screening
    • 3.3.4. Lead Generation
    • 3.3.5. Lead Optimization
  • 3.4. Overview of DNA Encoded Libraries
    • 3.4.1. Encoding Strategies for Library Construction
    • 3.4.2. Historical Evolution of DNA Encoded Libraries
    • 3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
    • 3.4.4. Key Advantages of DNA Encoded Libraries
    • 3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
  • 3.5. Future Perspectives and Opportunity Areas

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Type of Company / Organization
    • 4.2.6. Analysis by Library Size
    • 4.2.7. Analysis by Library Synthesis Method(s)
    • 4.2.8. Analysis by Library Screening Method(s)
    • 4.2.9. Analysis by Type of Product(s) Offered
    • 4.2.10. Analysis by Type of Service(s) Offered
      • 4.2.10.1. Analysis by Type of Library Design Service(s) Offered
      • 4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
    • 4.2.11. Analysis by Type of Pharmacological Lead(s)
    • 4.2.12. Analysis by Therapeutic Target(s)
    • 4.2.13. Analysis by Therapeutic Area(s)
    • 4.2.14. Analysis by End-user(s)

5. BUSINESS MODEL ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. DNA Encoded Library Companies: Business Model Analysis
    • 5.2.1. Analysis by Operational Model
      • 5.2.1.1. Analysis by Company Size and Operational Model
      • 5.2.1.2. Analysis by Location of Headquarters and Operational Model
    • 5.2.2. Analysis by Business Model
      • 5.2.2.1. Analysis by Service Centric Model
      • 5.2.2.2. Analysis by Product Centric Model
  • 5.3. Concluding Remarks

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
    • 6.4.1. DNA Encoded Library Companies based in North America
    • 6.4.2. DNA Encoded Library Companies based in Europe
    • 6.4.3. DNA Encoded Library Companies based in Asia-Pacific

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. AlphaMa
    • 7.2.1. Company Overview
    • 7.2.2. DNA Encoded Library Platform and Service Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. DICE Therapeutics
    • 7.3.1. Company Overview
    • 7.3.2. DNA Encoded Library Platform and Service Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. DyNAbind
    • 7.4.1. Company Overview
    • 7.4.2. DNA Encoded Library Platform and Service Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. HitGen
    • 7.5.1. Company Overview
    • 7.5.2. DNA Encoded Library Platform and Service Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. NovAliX
    • 7.6.1. Company Overview
    • 7.6.2. DNA Encoded Library Platform and Service Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. Vipergen
    • 7.7.1. Company Overview
    • 7.7.2. DNA Encoded Library Platform and Service Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. WuXi AppTec
    • 7.8.1. Company Overview
    • 7.8.2. DNA Encoded Library Platform and Service Portfolio
    • 7.8.3. Recent Developments and Future Outlook
  • 7.9. X-Chem
    • 7.9.1. Company Overview
    • 7.9.2. DNA Encoded Library Platform and Service Portfolio
    • 7.9.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. DNA Encoded Libraries: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Focus Area
    • 8.3.5. Analysis by Therapeutic Area
    • 8.3.6. Analysis by Type of Partner
      • 8.3.6.1 Analysis by Partner Company Size
    • 8.3.7. Most Active Players: Analysis by Number of Partnerships
    • 8.3.8. Analysis by Geography
      • 8.3.8.1. International and Local Agreements
      • 8.3.8.2. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. DNA Encoded Libraries: Funding and Investment Analysis
    • 9.3.1. Analysis of Instances by Year of Funding
    • 9.3.2. Analysis of Amount Invested by Year of Funding
    • 9.3.3. Analysis of Instances by Type of Funding
    • 9.3.4. Analysis of Amount Invested by Type of Funding
    • 9.3.5. Most Active Players: Analysis by Number of Funding Instances
    • 9.3.6. Most Active Players: Analysis by Amount Raised
    • 9.3.7. Most Active Investors: Analysis by Number of Instances
    • 9.3.8. Analysis by Geography
    • 9.3.9. Concluding Remarks

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. DNA Encoded Libraries: Patent Analysis
    • 10.3.1. Analysis by Patent Publication Year
    • 10.3.2. Analysis by Patent Application Year
    • 10.3.3. Analysis by Type of Patent and Publication Year
    • 10.3.4. Analysis by Patent Jurisdiction
    • 10.3.5. Analysis by CPC Symbols
    • 10.3.6. Analysis by Type of Applicant
    • 10.3.7. Leading Industry Players: Analysis by Number of Patents
    • 10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 10.3.9. Leading Individual Assignees: Analysis by Number of Patents
  • 10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
  • 10.5. DNA Encoded Libraries: Patent Valuation Analysis
  • 10.6. Leading Patents by Number of Citations

11. BIG PHARMA INITIATIVES

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
  • 11.4. Benchmark Analysis of Big Pharma Players
    • 11.4.1. Spider Web Analysis: AbbVie
    • 11.4.2. Spider Web Analysis: Amgen
    • 11.4.3. Spider Web Analysis: AstraZeneca
    • 11.4.4. Spider Web Analysis: Bayer
    • 11.4.5. Spider Web Analysis: Boehringer Ingelheim
    • 11.4.6. Spider Web Analysis: Eli Lilly
    • 11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
    • 11.4.8. Spider Web Analysis: Johnson & Johnson
    • 11.4.9. Spider Web Analysis: Merck
    • 11.4.10. Spider Web Analysis: Novartis
    • 11.4.11. Spider Web Analysis: Pfizer
    • 11.4.12. Spider Web Analysis: Sanofi
  • 11.5. Concluding Remarks

12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES

  • 12.1. Chapter Overview
  • 12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
    • 12.2.1. Analysis by Year of Establishment
    • 12.2.2. Analysis by Company Size
    • 12.2.3. Analysis by Location of Headquarters
    • 12.2.4. Analysis by Company Size and Location of Headquarters
    • 12.2.5. Analysis by Type of Company / Organization
    • 12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
    • 12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
    • 13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
      • 13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
      • 13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
      • 13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
      • 13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
    • 13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
      • 13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
      • 13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
      • 13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
      • 13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
      • 13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
      • 13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
      • 13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
      • 13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
    • 13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
      • 13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
      • 13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
      • 13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
    • 13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
      • 13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
      • 13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
    • 13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
      • 13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
        • 13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
      • 13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
        • 13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
        • 13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
        • 13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
        • 13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
        • 13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
        • 13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
      • 13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
        • 13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Vipergen
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
  • 15.3. Serengen
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
  • 15.4. Deluge Biotechnologies
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
  • 15.5. NovAliX
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
  • 15.6. Orbit Discovery
    • 15.6.1. Company Snapshot
    • 15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
  • 15.7. Anonymous

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 DNA Encoded Libraries: List of Service Providers / Platform Providers / In-House Companies
  • Table 4.2 DNA Encoded Libraries: Information on Library Size, Library Synthesis Method(s) and Library Screening Method(s)
  • Table 4.3 DNA Encoded Libraries: Information on Type of Product(s) and Service(s) Offered
  • Table 4.4 DNA Encoded Libraries: Information on Type of Pharmacological Lead(s) and Therapeutic Target(s)
  • Table 4.5 DNA Encoded Libraries: Information on Therapeutic Area(s) and End-user(s)
  • Table 5.1 DNA Encoded Libraries: Information on Company Size, Location of Headquarters and Operational Model
  • Table 5.2 DNA Encoded Libraries: Information on Business Model
  • Table 7.1 DNA Encoded Libraries: List of Companies Profiled
  • Table 7.2 AlphaMa: Company Snapshot
  • Table 7.3 AlphaMa: DNA Encoded Library Platform and Service Portfolio
  • Table 7.4 AlphaMa: Recent Developments and Future Outlook
  • Table 7.5 DICE Therapeutics: Company Snapshot
  • Table 7.6 DICE Therapeutics: DNA Encoded Library Platform and Service Portfolio
  • Table 7.7 DICE Therapeutics: Recent Developments and Future Outlook
  • Table 7.8 DyNAbind: Company Snapshot
  • Table 7.9 DyNAbind: DNA Encoded Library Platform and Service Portfolio
  • Table 7.10 DyNAbind: Recent Developments and Future Outlook
  • Table 7.11 HitGen: Company Snapshot
  • Table 7.12 HitGen: DNA Encoded Library Platform and Service Portfolio
  • Table 7.13 HitGen: Recent Developments and Future Outlook
  • Table 7.14 NovAliX: Company Snapshot
  • Table 7.15 NovAliX: DNA Encoded Library Platform and Service Portfolio
  • Table 7.16 NovAliX: Recent Developments and Future Outlook
  • Table 7.17 Vipergen: Company Snapshot
  • Table 7.18 Vipergen: DNA Encoded Library Platform and Service Portfolio
  • Table 7.19 Vipergen: Recent Developments and Future Outlook
  • Table 7.20 WuXi AppTec: Company Snapshot
  • Table 7.21 WuXi AppTec: DNA Encoded Library Platform and Service Portfolio
  • Table 7.22 X-Chem: Company Snapshot
  • Table 7.23 X-Chem: DNA Encoded Library Platform and Service Portfolio
  • Table 7.24 X-Chem: Recent Developments and Future Outlook
  • Table 8.1 DNA Encoded Libraries: List of Partnerships and Collaborations, 2010-2023
  • Table 9.1 DNA Encoded Libraries: List of Funding and Investments, 2018-2023
  • Table 10.1 Patent Analysis: Top CPC Sections
  • Table 10.2 Patent Analysis: Top CPC Symbols
  • Table 10.3 Patent Analysis: Top CPC Codes
  • Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 10.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 10.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 12.1 DNA Encoded Libraries: List of Supporting Companies / Organizations
  • Table 12.2 DNA Encoded Libraries: Information on Type of Support Services / Ancillary Tools Offered
  • Table 13.1 DNA Encoded Libraries: Average Upfront Payment and Average Milestone Payment, 2016-2022 (USD Million)
  • Table 13.2 Library Licensing Deals: Tranches of Milestone Payments
  • Table 15.1 Vipergen: Company Key Highlights
  • Table 15.2 Serengen: Company Key Highlights
  • Table 15.3 Deluge Biotechnologies: Company Key Highlights
  • Table 15.4 NovAliX: Company Key Highlights
  • Table 15.5 Orbit Discovery: Company Key Highlights
  • Table 16.1 DNA Encoded Libraries: Distribution by Year of Establishment
  • Table 16.2 DNA Encoded Libraries: Distribution by Company Size
  • Table 16.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
  • Table 16.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
  • Table 16.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
  • Table 16.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
  • Table 16.7 DNA Encoded Libraries: Distribution by Library Size
  • Table 16.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
  • Table 16.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
  • Table 16.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
  • Table 16.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
  • Table 16.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
  • Table 16.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
  • Table 16.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
  • Table 16.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
  • Table 16.16 DNA Encoded Libraries: Distribution by End-user(s)
  • Table 16.17 DNA Encoded Libraries: Distribution by Operational Model
  • Table 16.18 DNA Encoded Libraries: Distribution by Company Size and Operational Model
  • Table 16.19 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
  • Table 16.20 DNA Encoded Libraries: Distribution by Business Model
  • Table 16.21 DNA Encoded Libraries: Distribution by Service Centric Model
  • Table 16.22 DNA Encoded Libraries: Distribution by Product Centric Model
  • Table 16.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
  • Table 16.24 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 16.26 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
  • Table 16.27 Partnerships and Collaborations: Distribution by Focus Area
  • Table 16.28 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 16.29 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 16.30 Partnerships and Collaborations: Distribution by Partner Company Size
  • Table 16.31 Most Active Players: Distribution by Number of Partnerships
  • Table 16.32 Partnerships and Collaborations: International and Local Agreements
  • Table 16.33 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 16.34 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
  • Table 16.35 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
  • Table 16.36 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
  • Table 16.37 Funding and Investment: Distribution of Instances by Type of Funding
  • Table 16.38 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 16.39 Most Active Players: Distribution by Number of Funding Instances
  • Table 16.40 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 16.41 Most Active Investors: Distribution by Number of Instances
  • Table 16.42 Funding and Investment Analysis: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
  • Table 16.43 Funding and Investment Analysis: Distribution of Number of Instances by Geography (Country-wise)
  • Table 16.44 Funding and Investment Analysis: Summary of Investments by Number of Instances and Amount Invested (USD Million)
  • Table 16.45 Patent Analysis: Distribution by Type of Patent
  • Table 16.46 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
  • Table 16.47 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
  • Table 16.48 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
  • Table 16.49 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
  • Table 16.50 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
  • Table 16.51 Patent Analysis: Distribution by CPC Symbols
  • Table 16.52 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 16.53 Leading Industry Players: Distribution by Number of Patents
  • Table 16.54 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 16.55 Leading Individual Assignees: Distribution by Number of Patents
  • Table 16.56 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Table 16.57 Patent Analysis: Distribution by Patent Age
  • Table 16.58 Patent Analysis: Distribution by Relative Patent Valuation
  • Table 16.59 Big Pharma Players: Heat Map Analysis of Top Pharma Companies
  • Table 16.60 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
  • Table 16.61 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
  • Table 16.62 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
  • Table 16.63 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
  • Table 16.64 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
  • Table 16.65 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
  • Table 16.66 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
  • Table 16.67 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Opportunity, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
  • Table 16.68 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
  • Table 16.69 DNA Encoded Library Market for Hit Generation / Identification, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.70 DNA Encoded Library Market for Hit to Lead, Conservative, Base and Optimistic Scenarios, 2023-2035(USD Million)
  • Table 16.71 DNA Encoded Library Market for Hit Validation / Optimization, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.72 DNA Encoded Library Market for Other Application Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.73 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
  • Table 16.74 DNA Encoded Library Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.75 DNA Encoded Library Market for Immunological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.76 DNA Encoded Library Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.77 DNA Encoded Library Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.78 DNA Encoded Library Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.79 DNA Encoded Library Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.80 DNA Encoded Library Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.81 DNA Encoded Library Market for Other Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.82 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
  • Table 16.83 DNA Encoded Library Market for Pharma / Biopharma Industry, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.84 DNA Encoded Library Market for Academic / Research Institute, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.85 DNA Encoded Library Market for Other End-users, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.86 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
  • Table 16.87 DNA Encoded Library Market: Upfront Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.88 DNA Encoded Library Market: Milestone Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.89 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
  • Table 16.90 DNA Encoded Library Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.91 DNA Encoded Library Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.92 DNA Encoded Library Market in Denmark, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.93 DNA Encoded Library Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.94 DNA Encoded Library Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.95 DNA Encoded Library Market in Switzerland, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.96 DNA Encoded Library Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.97 DNA Encoded Library Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
  • Table 16.98 DNA Encoded Library Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)

List of Figures

  • Figure 2.1 Executive Summary: Market Landscape
  • Figure 2.2 Executive Summary: Business Model Analysis
  • Figure 2.3 Executive Summary: Partnerships and Collaborations
  • Figure 2.4 Executive Summary: Funding and Investment Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Drug Discovery and Development Timeline
  • Figure 3.2 Drug Discovery Process
  • Figure 3.3 Construction Process of a DNA Encoded Library
  • Figure 3.4 Encoding Strategies for Constructing DNA Encoded Libraries
  • Figure 3.5 Historical Evolution of DNA Encoded Libraries
  • Figure 3.6 Comparison of Traditional Libraries and DNA Encoded Libraries
  • Figure 3.7 Key Advantages of DNA Encoded Libraries
  • Figure 3.8 Challenges and Limitations Associated with DNA Encoded Libraries
  • Figure 4.1 DNA Encoded Libraries: Distribution by Year of Establishment
  • Figure 4.2 DNA Encoded Libraries: Distribution by Company Size
  • Figure 4.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
  • Figure 4.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
  • Figure 4.7 DNA Encoded Libraries: Distribution by Library Size
  • Figure 4.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
  • Figure 4.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
  • Figure 4.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
  • Figure 4.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
  • Figure 4.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
  • Figure 4.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
  • Figure 4.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
  • Figure 4.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
  • Figure 4.16 DNA Encoded Libraries: Distribution by End-user(s)
  • Figure 5.1 DNA Encoded Libraries: Distribution by Operational Model
  • Figure 5.2 DNA Encoded Libraries: Distribution by Company Size and Operational Model
  • Figure 5.3 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
  • Figure 5.4 DNA Encoded Libraries: Distribution by Business Model
  • Figure 5.5 DNA Encoded Libraries: Distribution by Service Centric Model
  • Figure 5.6 DNA Encoded Libraries: Distribution by Product Centric Model
  • Figure 6.1 Company Competitiveness Analysis: DNA Encoded Library Companies based in North America
  • Figure 6.2 Company Competitiveness Analysis: DNA Encoded Library Companies based in Europe
  • Figure 6.3 Company Competitiveness Analysis: DNA Encoded Library Companies based in Asia-Pacific
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
  • Figure 8.5 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.8 Partnerships and Collaborations: Distribution by Partner Company Size
  • Figure 8.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.10 Partnerships and Collaborations: International and Local Agreements
  • Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
  • Figure 9.2 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
  • Figure 9.3 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
  • Figure 9.4 Funding and Investment : Distribution of Instances by Type of Funding
  • Figure 9.5 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.7 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 9.8 Most Active Investors: Distribution by Number of Instances
  • Figure 9.9 Funding and Investment: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
  • Figure 9.10 Funding and Investment: Distribution of Number of Instances by Geography (Country-wise)
  • Figure 9.11 Funding and Investment: Summary of Investments by Number of Instances and Amount Invested (USD Million)
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
  • Figure 10.3 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
  • Figure 10.4 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
  • Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
  • Figure 10.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
  • Figure 10.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 10.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.11 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 10.13 Patent Analysis: Distribution by Patent Age
  • Figure 10.14 Patent Analysis: Distribution by Relative Patent Valuation
  • Figure 11.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharma Companies
  • Figure 11.2 Spider Web Analysis: AbbVie
  • Figure 11.3 Spider Web Analysis: Amgen
  • Figure 11.4 Spider Web Analysis: AstraZeneca
  • Figure 11.5 Spider Web Analysis: Bayer
  • Figure 11.6 Spider Web Analysis: Boehringer Ingelheim
  • Figure 11.7 Spider Web Analysis: Eli Lilly
  • Figure 11.8 Spider Web Analysis: GlaxoSmithKline (GSK)
  • Figure 11.9 Spider Web Analysis: Johnson & Johnson
  • Figure 11.10 Spider Web Analysis: Merck
  • Figure 11.11 Spider Web Analysis: Novartis
  • Figure 11.12 Spider Web Analysis: Pfizer
  • Figure 11.13 Spider Web Analysis: Sanofi
  • Figure 12.1 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
  • Figure 12.2 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
  • Figure 12.3 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
  • Figure 12.4 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
  • Figure 12.5 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
  • Figure 12.6 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
  • Figure 12.7 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
  • Figure 13.1 Licensing Agreements: Distribution of Financial Components
  • Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
  • Figure 13.3 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035 (USD Billion)
  • Figure 13.4 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
  • Figure 13.5 DNA Encoded Library Market for Hit Generation / Identification, 2023-2035 (USD Million)
  • Figure 13.6 DNA Encoded Library Market for Hit to Lead, 2023-2035(USD Million)
  • Figure 13.7 DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035 (USD Million)
  • Figure 13.8 DNA Encoded Library Market for Other Application Areas, 2023-2035 (USD Million)
  • Figure 13.9 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
  • Figure 13.10 DNA Encoded Library Market for Oncological Disorders, 2023-2035 (USD Million)
  • Figure 13.11 DNA Encoded Library Market for Immunological Disorders, 2023-2035 (USD Million)
  • Figure 13.12 DNA Encoded Library Market for Neurological Disorders, 2023-2035 (USD Million)
  • Figure 13.13 DNA Encoded Library Market for Respiratory Disorders, 2023-2035 (USD Million)
  • Figure 13.14 DNA Encoded Library Market for Dermatological Disorders, 2023-2035 (USD Million)
  • Figure 13.15 DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035 (USD Million)
  • Figure 13.16 DNA Encoded Library Market for Infectious Diseases, 2023-2035 (USD Million)
  • Figure 13.17 DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035 (USD Million)
  • Figure 13.18 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
  • Figure 13.19 DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035 (USD Million)
  • Figure 13.20 DNA Encoded Library Market for Academic / Research Institute, 2023-2035 (USD Million)
  • Figure 13.21 DNA Encoded Library Market for Other End-users, 2023-2035 (USD Million)
  • Figure 13.22 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
  • Figure 13.23 DNA Encoded Library Market: Upfront Payments, 2023-2035 (USD Million)
  • Figure 13.24 DNA Encoded Library Market: Milestone Payments, 2023-2035 (USD Million)
  • Figure 10.25 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
  • Figure 13.26 DNA Encoded Library Market in the US, 2023-2035 (USD Million)
  • Figure 13.27 DNA Encoded Library Market in Europe, 2023-2035 (USD Million)
  • Figure 13.28 DNA Encoded Library Market in Denmark, 2023-2035 (USD Million)
  • Figure 13.29 DNA Encoded Library Market in Germany, 2023-2035 (USD Million)
  • Figure 10.30 DNA Encoded Library Market in UK, 2023-2035 (USD Million)
  • Figure 13.31 DNA Encoded Library Market in Switzerland, 2023-2035 (USD Million)
  • Figure 13.32 DNA Encoded Library Market in France, 2023-2035 (USD Million)
  • Figure 13.33 DNA Encoded Library Market in Rest of the Europe, 2023-2035 (USD Million)
  • Figure 13.34 DNA Encoded Library Market in China, 2023-2035 (USD Million)
  • Figure 14.1 Concluding Remarks: Market Landscape
  • Figure 14.2 Concluding Remarks: Business Model Analysis
  • Figure 14.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 14.4 Concluding Remarks: Funding and Investment Analysis
  • Figure 14.5 Concluding Remarks: Patent Analysis
  • Figure 14.6 Concluding Remarks: Market Forecast and Opportunity Analysis